

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/207712 A3

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/82 (2006.01)
C12N 15/00 (2006.01) C07H 21/04 (2006.01)

(21) International Application Number:

PCT/US2021/026732

(22) International Filing Date:

09 April 2021 (09.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/007,803	09 April 2020 (09.04.2020)	US
63/007,797	09 April 2020 (09.04.2020)	US
63/045,032	26 June 2020 (26.06.2020)	US
63/045,033	26 June 2020 (26.06.2020)	US
63/136,087	11 January 2021 (11.01.2021)	US

(71) Applicant: **VERVE THERAPEUTICS, INC.** [US/US];
500 Technology Square, Suite 901, Cambridge, Massachu-
setts 02139 (US).

(72) Inventors: **CHADWICK, Alexandra**; 500 Technology
Square, Suite 901, Cambridge, Massachusetts 02139 (US).
RAJEEV, Kallanthottathil G.; 500 Technology Square,
Suite 901, Cambridge, Massachusetts 02139 (US). **RO-
HDE, Ellen**; 500 Technology Square, Suite 901, Cam-
bridge, Massachusetts 02139 (US). **CHENG, Christopher**;
500 Technology Square, Suite 901, Cambridge, Massa-
chusetts 02139 (US). **REISS, Caroline**; 500 Technology
Square, Suite 901, Cambridge, Massachusetts 02139 (US).

(74) Agent: **UM, Moonkyoung**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE




FIG. 34

(57) Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

16 December 2021 (16.12.2021)